Research
Filter News
Found 147,984 articles
-
Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com’s Supplier Pre-assessment Program
4/9/2024
Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i ® , Scientist.com’s Supplier Pre-assessment Program.
-
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
4/9/2024
Nurix Therapeutics, Inc. announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6).
-
Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders
4/9/2024
Vanqua Bio announced that the first patient has been dosed in a first-in-human Phase 1 clinical study evaluating VQ-101 in healthy individuals and patients with various forms of Parkinson’s disease (PD).
-
GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
4/9/2024
GT Medical Technologies, Inc. today announced it has enrolled the 100th patient in its ROADS clinical study. ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).
-
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
4/9/2024
ProMIS Neurosciences Inc. today announced the publication of supportive preclinical data in the Journal of Biological Chemistry in an article titled, “Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1."
-
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
4/9/2024
ALX Oncology Holdings Inc. reported encouraging clinical data from the ongoing Phase 1/2 investigator-sponsored trial of evorpacept in combination with R2 in patients with indolent and aggressive R/R B-NHL.
-
Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery
4/9/2024
Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.
-
American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer
4/9/2024
Lung cancer remains the leading cause of cancer deaths in the United States, with someone diagnosed approximately every two minutes.
-
Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines
4/9/2024
Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines.
-
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
4/9/2024
Calidi Biotherapeutics Inc. today announced the presentation of new data detailing the molecular mechanisms of action underlying the immunomodulatory role of Calidi’s therapies at the American Association for Cancer Research Annual (AACR) Meeting 2024, in San Diego, California.
-
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
4/9/2024
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.
-
COVID-19 Virus Can Persist in the Body More Than a Year after Infection
4/9/2024
Research published in Lancet Infectious Diseases and supported by PolyBio Research Foundation provides the strongest evidence yet that the COVID virus can persist for months or years after infection.
-
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study
4/9/2024
Immunovia, the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test.
-
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
4/9/2024
Seres Therapeutics, Inc. announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).
-
CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center
4/9/2024
Clinical Laserthermia Systems Americas, Inc. announced it has received its second order from the National Institutes of Health Clinical Center for its TRANBERG™ Thermal Therapy System accessories.
-
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
4/9/2024
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO ® in Adults Aged 18 to 59 at Increased Risk for RSV Disease.
-
Researchers are working to optimize the properties of antibody-drug conjugates in order to maximize clinical efficacy while minimizing the risk of toxicities.
-
Ichnos Glenmark Innovation Presents Preclinical Data for its Oncology Asset ISB 2001 at AACR 2024 Annual Meeting
4/8/2024
Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company developing multispecifics™ in oncology, and Glenmark Pharmaceuticals Ltd., shared preclinical data for its oncology asset ISB 2001 during the oral presentation at the annual American Association for Cancer Research (AACR) 2024.
-
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor
4/8/2024
C4 Therapeutics, Inc. presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor.
-
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
4/8/2024
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.